Lung cancer is classified into two major categories: non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases, and small-cell lung cancer (SCLC), which accounts for the ...

Danielle Hicks, Nisha Mohindra, MD, and Christopher Towe, MD, share their perspectives and offer advice to those navigating an early-stage non-small cell lung cancer diagnosis. Sponsored by Bristol ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK+ Non-small Cell Lung Cancer ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called imfinzi (durvalumab). Immunotherapy ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Non-small cell lung cancer (NSCLC) is the most common kind of lung cancer, making up about 80 to 85 percent of all cases, according to the American Cancer Society (ACS). It’s referred to as metastatic ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an unprecedented gain in progression-free survival (PFS) for ALK-positive ...